Search results for: 'label facil biosensor detection'

The growth trajectory of the global life sciences industry has benefited from a combination of novel technologies such as CRISPR-Cas9, microbiome and single-cell, relaxation of entry barriers in markets like China, and better-defined regulatory frameworks around next-generation therapies and companion diagnostics. A common denominator of growth a...

Continuous manufacturing (CM) is a method for manufacturing end-to-end pharmaceutical products on a single, uninterrupted production line. While batch manufacturing requires transporting, testing, and refeeding materials from one process to the next, continuous processes execute all testing, feeding, and processing inline at a single manufacturing ...

05 Apr 2023  |  Asia Pacific  |  Market Outlook

Asia-Pacific Pharmaceutical Industry Outlook, 2023

Disruptive Technology Adoption and Outsourcing Growth is Advancing Innovation in the Pharmaceutical Industry

Infographics

×

Asia-Pacific’s pharmaceutical market is forecast to record 4.2% growth from 2022 to 2027, with China and Japan dominating the market in terms of value. Generics dominate the regional markets based on volume, directly impacting innovator molecule uptake. Nevertheless, Asia-Pacific is establishing itself as a global innovation hub, with China, Japan,...

The Transformational Health team at Frost & Sullivan provides critical insights into the US and EU upstream bioprocessing market, highlighting drug demand trends, installed capacity developments, market revenue forecast by various segments, competitive landscape, and key growth opportunities that currently exist or are set to develop during the for...

Globally, diagnosis of metabolic diseases such as type 2 diabetes and obesity have increased. Since the COVID-19 pandemic, the global prevalence of obesity has worsened. Obesity is considered a main precursor of diabetes and contributes an estimated 80% to 85% toward the risk of type 2 diabetes. As a result, the financial burden associated with hea...

Therapeutically more effective drugs for the treatment of chronic diseases represents a crucial need. Biosimilars and biobetters offer the possibility to lower the cost of treating a variety of chronic diseases. In particular, biosimilars are the less expensive option; however, biobetters have demonstrated to be more effective, even over longer per...

Overall Impact of Biomanufacturing Technology Innovations Impact on Unmet Needs Pharmaceutical companies perceive analytical services as important. There is a need for a robust platform that enables the provision of such services. Pharma firms are outsourcing crucial processes and are utilizing services such as analytics, research, process developm...

In 2003, the first human genome sequence was produced, with a production cost between $500 million and $1 billion. However, since 2008, when next-generation sequencing (NGS) approaches entered the research setting, there has been a significant decline in sequencing costs. These approaches allow either the whole genome (via whole-genome sequencing [...